Financials data is unavailable for this security.
View more
Year on year Concord Biotech Ltd grew revenues 19.20% from 8.53bn to 10.17bn while net income improved 28.33% from 2.40bn to 3.08bn.
Gross margin | 77.16% |
---|---|
Net profit margin | 30.18% |
Operating margin | 37.28% |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Concord Biotech Ltd increased its cash reserves by 332.73%, or 116.43m. The company earned 2.65bn from its operations for a Cash Flow Margin of 26.10%. In addition the company used 1.55bn on investing activities and also paid 992.15m in financing cash flows.
Cash flow per share | 35.07 |
---|---|
Price/Cash flow per share | 62.20 |
Book value per share | -- |
---|---|
Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
Current ratio | -- |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items increased 28.33%.
Div yield(5 year avg) | 0.12% |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | 29.23% |
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 27.64 |
More ▼